alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Tôi tên là Mariela và Câu Chuyện Của Tôi Có Thể Thay Đổi Cuộc Đời Bạn.

Tôi cảm thấy không khoẻ vào lúc Đáng lẽ tôi phải ở nhà, nhưng tôi cảm Tại chỗ làm, tôi nhóp những miếng khoai tây Có một gia đình đang tổ chức tiệc sinh nhật 

nửa đêm, nhưng tôi phải đi làm vào thấy khoẻ hơn. Tôi không biết rằng chiên bằng tay trần. lần thứ tư cho con trai của họ. Cậu bé tên là 

ngày sau đó. những mầm bệnh do trận ốm của tôi Jose Antonio.

vẫn còn ở trên tay.

Jose Antonio rất thích khoai tây chiên mà tôi Trong khi tôi đang ốm ở nhà, các báo cáo bắt đầu gửi đến phòng y tế Nếu có thể làm lại, tôi đã không bao giờ đi làm vào 

phục vụ cho cậu bé. Tôi trở về nhà một giờ sau từ khắp nơi. Toàn bộ, hơn 20 người đã bị bệnh do ăn tại nhà hàng của ngày đó. Tôi cũng có con, nên tôi không thể xoá 

đó bởi cảm thấy mệt trở lại. Tôi tiếp tục ốm hai chúng tôi. Họ xác nhận rằng tôi đã phục vụ cho tất cả những người hình ảnh của cậu bé Jose Antonio ra khỏi tâm trí 

ngày nữa. đang bị bệnh. mình. Cậu bé đã bị bệnh do tôi gây ra.

Hãy Bảo Vệ Mọi Người Ở Mọi Nơi. 

Hãy ở nhà nếu bạn bị ốm.
Tony Lee SIRMONS, Appellant, v. STATE of Florida, Appellee.

No. 4D19-1086

District Court of Appeal of Florida, Fourth District.

[June 13, 2019]

**DECISION WITHOUT PUBLISHED OPINION**

*Affirmed.*
HPVとは何ですか?

HPV(ヒトパピローマ ウイルス) は、性的に感

染するウイルスです。それは性器の接触(膣や肛

門のセックスなど)を介して、感染します。ま

た、皮膚と皮膚との接触によっても伝染します。

セックスをしたことがある人の少なくとも50%

は、人生のある時期にHPVに感染します。

HPVを聞いたことがな

いのは、なぜですか?

HPVは新しいウイルスではありません。しかし、

多くの人はそれについて知りません。殆どの人

は、症状がありません。HPVは健康上の問題を引

き起こすことなく、自然に消える可能性もあり

ます。

FDA婦人健康部 

www.fda.gov/womens

HPVに感染する可能性があ

るのは、どんな人ですか?

他人の性器に接触したことがある人は、誰でもHPVに感染

している可能性があります。男性も女性も、知らずに感染

し、他の人に伝染する可能性があります。兆候が無いこと

があるため、セックスをしてから数年経過しても気が付か

ぬままHPVに感染していることがあります。

 の場合、HPVに感染する可能性が高くなります:

• 早い年齢でセックスする

• 自分に多くのセックスパートナーが居る、または

• 多くのパートナーが居るセックスパートナーとセ ックス

する。

症状が無いのに、なぜHPV

を心配する必要があるので

すか?

HPVは100種類以上あり、全てが健康上の問題を引き起こす

わけではありません。HPVの種類によっては、性器にイボ

などの問題を引き起こす可能性があります。別のHPVの種類

は、子宮頸がん、膣がん、外陰がん、肛門がんを引き起こ

すこともあります。これらの問題の殆どは、タイプ6、11

、16、または18によって引き起こされます。

HPVの治療法はあります

か?

ウイルス(HPV)自体に、完治治療法はありません。 生殖

器疣贅(イボ)、子宮頸部の変化、子宮頸がんなど、HPVが

引き起こす可能性のある健康上の問題に対しては、治療法

があります。

生殖器疣贅(イボ)につい

て知っておくべきことはあ

りますか? 

生殖器疣贅には多くの治療法の選択肢があります。しか

し、疣贅(イボ)が治療された後でも、ウイルスはまだそ

こにあり、他の人に伝染する可能性があります。生殖器疣

贅を治療しない場合、自然に消えるか、同じままである

か、サイズや数が増えたりする可能性はありますが、癌に

なることはありません。

HPV(ヒトパピロ

ーマ ウイルス)
HPV(ヒトパピローマ ウイルス)

このファクトシートは、FDA婦人保健部によって作成されました。 

女性特有の他の健康に関してのリソースは、下記のサイトを訪問してください。

www.fda.gov/womens

2021

子宮頸がんについて知っ

ておくべきことはありま

すか?

全ての女性は定期的に子宮頸がん細胞診(Papテスト)

を受ける必要があります。細胞診では、HPVによって引

き起こされる細胞の変化を探します。この検査は細胞

の変化を早期に発見するため、細胞が癌になる前に子

宮頸部を治療することができます。この検査はまた、

癌を初期段階で発見できるため、重度になる前に治療

することができます。子宮頸がんが早期に発見された

場合、子宮頸がんで死亡することは殆どありません。

膣がんまたは外陰がんに

ついて知っておくべきこ

とはありますか?

膣がんは、膣(産道)のがんです。外陰がんは、陰

核、膣唇、および膣の開口部のがんです。これらの癌

は、両方とも非常に稀です。全ての膣がんまたは外陰

がんが、HPVが原因とは限りません。

肛門がんについて知って

おくべきことはあります

か?

肛門がんは、肛門の組織に発生するがんです。肛門

は、直腸(大腸の最後の部分)の体の外側への開口部

です。

HPVの検査はあります

か?

あります。 子宮頸がんを引き起こす可能性のある

HPVの種類を検査します。FDAは、HPV検査を30歳以上

の女性に行うことを承認しました。子宮頸部に変化

が起こる前でも、HPVが発見される可能性がありま

す。HPV検査を受けていても、女性は別に子宮頸がん

細胞診(Papテスト)は受ける必要があります。

HPVを予防することは出

来ますか?

FDAは、ある種のHPVによって引き起こされる子宮頸

がんなど、特定の病気を予防するワクチンを承認し

ています。HPVワクチンを接種すべきかどうかは、医

師に相談してください。

HPVに感染する可能性を

下げるために、他に何

ができますか?

• セックスをしない(禁欲する)選択があります。

• セックスをしている場合は、パートナーの数を制

限します

• セックスパートナーが他にいないか、殆どいない

パートナーを選びます。あなたのパートナーのパ

ートナーの数が少なければ少ないほど、彼または

彼女がHPVに感染する可能性は低くなります

• コンドームがHPVをどれだけ予防するかは、不明で

す。コンドームに覆われていない部分は、ウイルス

に晒される可能性があります。

HPV(ヒトパピローマ ウイルス)(JAPANESE)
Joseph Edward McCONNEL, petitioner, v. UNITED STATES.

No. 12-9500.

Supreme Court of the United States

April 29, 2013.

Motion of petitioner for leave to proceed *in forma pauperis* denied. Petitioner allowed until May 20, 2013, within which to pay the docketing fee required by Rule 38(a) and to submit a petition in compliance with Rule 33.1 of the Rules of this Court.
Eugene E. ISAACSON, petitioner, v. Shawn BERRIGAN, et al.

No. 12-8783.

Supreme Court of the United States

April 22, 2013.

Motion of petitioner for leave to proceed *in forma pauperis* denied. Petitioner allowed until May 13, 2013, within which to pay the docketing fee required by Rule 38(a) and to submit a petition in compliance with Rule 33.1 of the Rules of this Court.
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 1 of 7
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 2 of 7
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 3 of 7
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 4 of 7
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 5 of 7
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 6 of 7
case 3:13-cv-00162-PPS-CAN document 1 filed 03/05/13 page 7 of 7
Exhibit 23.4


Consent of Independent Auditors





The Board of Directors


Kennedy-Wilson Holdings, Inc.:


We consent to the use of our report dated March 28, 2014, with respect to the consolidated statements of operations, changes in shareholders' equity, and cash flows of Egret Limited for the year ended December 31, 2013, incorporated by reference in the registration statements (No. 333-174742, No. 333-175002, No. 333-175559, No. 333-184752, and No. 333-192059) on Form S-3, the registration statements (No. 333-164928, No. 333-182269, and No. 333-197492) on Form S-8, the registration statement (No. 333-164926) on Form S-1/A and the registration statement (No. 333-186690) on Form S-4 of Kennedy-Wilson Holdings, Inc. in reliance upon the report of KPMG, independent auditors, which report appears in amendment no. 1 to the December 31, 2015 annual report on Form 10-K of Kennedy-Wilson Holdings, Inc.





/s/ KPMG


Dublin, Ireland


March 25, 2016
<PAGE>

                                                                    EXHIBIT 32.1





                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



         In connection with the Quarterly Report of Alpha Technologies Group,
Inc. (the "Company") on Form 10-Q/A-1 for the period ending January 25, 2004 as
filed with the Securities and Exchange Commission on the date hereof ("Report"),
Lawrence Butler, Chief Executive Officer of the Company, and James J.
Polakiewicz, Chief Financial Officer of the Company, each certify, pursuant to
18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that to the best of my knowledge:

         (1)      The Report fully complies with the requirements of section
                  13(a) or 15(d) of the Securities and Exchange Act of 1934; and

         (2)      The information contained in the Report fairly presents, in
                  all material respects, the financial condition and result of
                  operations of the Company.

Date: May 14, 2004            By: /s/ Lawrence Butler
                                  ----------------------------------------------
                                  Lawrence Butler
                                  Chief Executive Officer
                                  (Principal Executive Officer)



Date: May 14, 2004            By: /s/ James J. Polakiewicz
                                  ----------------------------------------------
                                  James J. Polakiewicz
                                  Chief Financial Officer
                                  (Principal Financial and Accounting Officer)


         The foregoing certification is being furnished solely pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of
Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed
as part of the Form 10-Q/A-1 or as a separate disclosure document.

         A signed original of this written statement required by Section 906 has
been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.
DEPARTMENT OF REVENUE , Appellant,

v. TIMEIKA DELOISE AQUAVIA LATTERY MCGILL and LESLY ST. CLOU , Appellee s . IN THE DISTRICT COURT OF APPEAL FIRST DISTRICT, STATE OF FLORIDA
NOT FINAL UNTIL TIME EXPIRES TO FILE MOTION FOR REHEARING AND DISPOSITION THEREOF IF FILED
CASE NO. 1D 15

- 716

_____________________________/ Opinion filed January 6, 201 6

. An appeal from an order of the Department of Revenue. Pamela Jo Bondi, Attorney General, and Toni C. Bernstein, Assistant Attorney General, Tallahassee , for Appellant. No Appearance for Appellee s .

PER CURIAM. The Florida Department of Revenue raises two issues in this appeal of a Final Administrative Support Order determining the child support obligation of Appellee Lesly St. Clou (the father). In the first issue, the Department argues that the administrative law judge (ALJ) erred by concluding that he lacked authority to enter a support order exceeding the amounts set forth in the Department’s2 Proposed Final Administrative Support Order based on new i nformation developed at an evidentiary hearing that would increase the father’s child support obligation under the statutory child support guidelines. In the second issue, the Department argues that the Final Administrative Support Order is not supported b y competent, substantial evidence. Consistent with our opinion in Department of Revenue v. Reyes , No. 1D15

- 707 (Fla. 1st DCA December 31 , 2015), we resolve both issues by concluding that the ALJ was required to establish the father’s child support obligati on based on the evidence presented at the hearing. By limiting the father’s child support obligation to the amounts contained in the proposed order, notwithstanding the evidence presented, the Final Administrative Support Order is contrary to Florida law a nd not supported by competent, substantial evidence. Accordingly, we vacate the order and remand for further proceedings.
WETHERELL , ROWE , and RAY , J J

. , CONCUR.
心臓の健康

心臓病は男性のみに起こると思ってい

るかもしれません。それは正しくありま

せん。 心臓病は、女性の主たる死亡原

因です。 

FDAは、心臓について適切な判断を下

すのに役立つヒントを提供しています。

FDA婦人保健部

www.fda.gov/womenshearthealth 

アスピリンについて

の事実。

心臓発作や脳卒中を防ぐために毎日アスピリ

ンを服用することは、全ての人にとって正しいこ

とではありません。

•アスピリンを服用すべきかどうかは、医師に尋ね

てください。

•

‐服用量。

 ‐服用頻度。

 ‐服用期間。製品によってはアスピリンと他の成

分の複合薬になっていて、長期服用に適さない

ものもあるので、注意してください。

• 自分が服用している全ての薬とサプリを、医師

に伝えてください。一部の薬、ビタミン剤、または

ハーブを併用しながらアスピリンを服用すると、

出血のリスクが高くなる可能性があります。

心臓発作の兆候を

知る。

心臓発作の兆候は、女性と男性の場合で異

なる場合があります。

• 胸、または、背中の肩甲骨の間の、激しい痛み

• 上半身の鋭い痛み

• 呼吸困難

• 冷や汗をかく

• 異常な、または、原因不明の、倦怠感

• めまいや立ちくらみ

• 胃の調子が悪い
心臓の健康

このファクトシートは、FDA婦人保健部によって作成されました。

女性の心臓の健康に関して詳しい情報を得るには、FDAのサイトを訪問してください。:

www.fda.gov/womenshearthealth

自分の健康状

態を管理する。

高血圧、糖尿病、高コレステ

ロールなどの良くある健康上

の問題は、心臓病のリスクを

高める可能性があります。

• 医師の指示通りに薬を服用してくださ

い。医師が大丈夫だと言うまで、薬の

服用を止めないでください。

• 糖尿病の人は、血糖値を定期的に測

定してください。

• 血圧とコレステロール値を定期的に

測定してください。

• 妊娠中の健康管理をどのようにすべ

きか、医師に相談してください。

• 一部の女性は、心臓の働きを助ける

ための装置を必要とします。自分の心

臓の状態に使うべき最適なデバイス

については、医師に相談してください。

2020

心臓に良い食事

を摂取する。

食品ラベルに記述されている栄養成

分は、健康的な食品を選ぶのに役立

ちます。

「低塩」または「低ナトリウム」の食品 

を選んでください。

「トランス脂肪酸」を含む食品の摂取 

を制限しましょう。トランス脂肪酸を取

りすぎると、心臓発作を引き起こす可

能性があります。

• 糖分を減らしましょう。砂糖は、「ブドウ

糖」、「果糖」、「ショ糖」、「コーンシロッ

プ」と書かれているものも含みます。

心臓の健康 (JAPANESE)
---

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO18 U.S.C. SECTION 1350,AS
ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of All American Gold Corp.
(the Company) on Form 10-KA for the year ended May 31, 2013, as filed with the
Securities and Exchange Commission on the date hereof (the Annual Report), I,
Gaspar R. Gonzalez, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

|1. | the Annual Report fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
  and                                   
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                        
|2. | the information contained in the Annual Report fairly
      presents, in all material respects, the financial condition and results of
      operations of the Company.

Date: November 6, 2013

/s/ Gaspar R. Gonzalez
  Gaspar R. Gonzalez 
  Chief Financial
Officer

A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this
written statement required by Section 906, has been provided to All American
Gold Corp. and will be retained by All American Gold Corp. and furnished to the
Securities and Exchange Commission or its staff upon request.

---
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

WAYMO LLC,

Plaintiff,

 v.

UBER TECHNOLOGIES, INC., et al.,

Defendants. /

No. C 17-00939 WHA

ORDER RE MEET AND

CONFER ON SPECIAL

MASTER’S PROTOCOL

The special master and counsel for both sides shall please meet and confer and submit

an agreed-upon revised version of the special master’s proposed monitoring and verification

protocol (Dkt. No. 462) by MAY 23 AT NOON. The revised version should make clear that any

action taken by the special master pursuant to the protocol is not subject to any promise of

confidentiality. For example, if the special master interviews an employee of defendants, he

must disclose the contents of that interview as needed or as the Court requires.

IT IS SO ORDERED.

Dated: May 20, 2017. WILLIAM ALSUP

UNITED STATES DISTRICT JUDGE

Case 3:17-cv-00939-WHA Document 482 Filed 05/20/17 Page 1 of 1
Michael PEACOCK, petitioner, v. Michael D. CREWS, Secretary, Florida Department of Corrections.

No. 12-8721.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
UNITED STATES JUDICIAL PANEL

on

MULTIDISTRICT LITIGATION

IN RE: BIOMET M2A MAGNUM HIP IMPLANT

PRODUCTS LIABILITY LITIGATION MDL No. 2391

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO −24)

On October 2, 2012, the Panel transferred 8 civil action(s) to the United States District Court for the

Northern District of Indiana for coordinated or consolidated pretrial proceedings pursuant to 28

U.S.C. §1407. See _F.Supp.2d_ (J.P.M.L. 2012). Since that time, 142 additional action(s) have been

transferred to the Northern District of Indiana. With the consent of that court, all such actions have

been assigned to the Honorable Robert L Miller, Jr.

It appears that the action(s) on this conditional transfer order involve questions of fact that are

common to the actions previously transferred to the Northern District of Indiana and assigned to

Judge Miller.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict

Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. §1407 to the

Northern District of Indiana for the reasons stated in the order of October 2, 2012, and, with the

consent of that court, assigned to the Honorable Robert L Miller, Jr.

This order does not become effective until it is filed in the Office of the Clerk of the United States

District Court for the Northern District of Indiana. The transmittal of this order to said Clerk shall be

stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the

Panel within this 7−day period, the stay will be continued until further order of the Panel.

FOR THE PANEL:

 Jeffery N. Lüthi

Clerk of the Panel

Case NV/2:13-cv-00212 Document 4 Filed 02/27/13 Page 1 of 2

Feb 27, 2013
IN RE: BIOMET M2A MAGNUM HIP IMPLANT

PRODUCTS LIABILITY LITIGATION MDL No. 2391

SCHEDULE CTO−24 − TAG−ALONG ACTIONS

DIST DIV. C.A.NO. CASE CAPTION

CALIFORNIA NORTHERN

CAN 3 13−00534 Haywood et al v. Biomet, Inc. et al

FLORIDA MIDDLE

FLM 2 13−00098 Milo v. Biomet, Inc. et al

FLM 2 13−00103 Cavanaugh v. Biomet, Inc. et al

GEORGIA SOUTHERN

GAS 2 12−00206 Bignault et al v. Biomet, Inc. et al

ILLINOIS NORTHERN

ILN 1 13−00983 Bermes v. Biomet, Inc et al

NEVADA

NV 2 13−00212 Gardberg v. Biomet, Inc. et al

NV 2 13−00213 Krom v. Biomet, Inc. et al

PENNSYLVANIA EASTERN

PAE 5 13−00714 PARSONS v. BIOMET, INC. et al

TEXAS SOUTHERN

TXS 4 13−00322 Tucker v. Biomet, Inc. et al

WEST VIRGINIA NORTHERN

WVN 1 12−00178 Dunson v. Biomet, Inc. et al

WEST VIRGINIA SOUTHERN

WVS 6 13−02217 West, et al v. Biomet, Inc., et al

Case NV/2:13-cv-00212 Document 4 Filed 02/27/13 Page 2 of 2
Abdela TUM, petitioner, v. UNITED STATES.

No. 12-10121.

Supreme Court of the United States

June 3, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the First Circuit denied.
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

United States District Court 

Northern District of Californi

a

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

RYAN REESE, 

Plaintiff, 

v. 

TRANSUNION, LLC., AVANT, INC., 

DESERT SPRINGS HOSPITAL MEDICAL 

CENTER, EMERGENCY MEDICINE 

PHYSICIANS OF CLARK SAINT ROSE 

MCCOURT, PLLC, and PROVIDENCE 

MEDICAL CENTER, 

Defendants. 

Case No. 17-cv-00388-JSW 

ORDER CONTINUING CASE 

MANAGEMENT CONFERENCE; AND 

ORDER TO PLAINTIFF TO SHOW 

CAUSE 

Re: Dkt. No. 27 

 The Court has received the parties’ joint case management conference statement. On April 

18, 2017, Plaintiff filed a notice that he had reached a settlement with Desert Springs Hospital 

Medical Center (“Desert Springs”) and stated that he anticipated a dismissal would be filed within 

thirty (30) days. (Dkt. No. 26.) Plaintiff confirms that position in the joint case management 

conference statement, but he has not yet dismissed Desert Springs. (Dkt. No. 27, Joint Case 

Management Conference Statement at 10:26-27.) 

The only other named defendants that remain in this case are Emergency Medicine 

Physicians of Clark Saint Rose McCourt, PLLC and Providence Medical Center (the “Unserved 

Defendants”). Plaintiff filed his Complaint on January 25, 2017, and he had until April 25, 2017 

to serve the Unserved Defendants. Plaintiff has not filed a proof of service on the Unserved 

Defendants. 

Accordingly, Plaintiff is HEREBY ORDERED TO SHOW CAUSE why the Court should 

not dismiss the case as to the Unserved Defendants based on the failure to comply with Federal 
United States District Court 

Northern District of Californi

a

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

Ru

wit

sho

lea

fail

no 

Jun

due

to a

Da

ule of Civil P

thin the time

ould file a pr

ave of court t

lure to comp

later than M

The Co

ne 16, 2017 a

e on June 9, 

appear. 

IT IS S

ated: May 1, 

Procedure 4(m

e period set f

roof of servi

to extend the

ply with Rule

May 15, 2017

ourt CONTIN

at 11:00 a.m

2017. If Pla

SO ORDER

2017 

m). If Plain

forth in Rule

ce. If Plaint

e time in wh

e 4(m). Plai

7. 

NUES the ca

m., and the pa

aintiff has di

RED. 

2

tiff has serve

e 4(m), when

tiff has not y

ich he has to

intiff’s respo

ase managem

arties’ joint c

ismissed Des

___

JEF

Un

ed either, or

n he respond

yet served th

o serve them

onse to this O

ment confere

case manage

sert Springs

__________

FFREY S. W

nited States D

r both, of the

ds to this Ord

he Unserved 

m, he must sh

Order to Sho

ence schedul

ement confer

by that date

___________

WHITE 

District Judg

e Unserved D

der to Show 

Defendants

how good ca

ow Cause sh

le for May 5

rence statem

e, it will not 

__________

ge 

Defendants 

Cause, he 

and seeks 

ause for his 

all be due by

, 2017 to 

ment shall be 

be required 

________ 

y
[Federal Register Volume 60, Number 94 (Tuesday, May 16, 1995)]
[Notices]
[Page 26040]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11942]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute of Child Health and Human Development; Meeting 
of the Board of Scientific Counselors, NICHD

    Pursuant to Pub. L. 92-463, notice is hereby given of the meeting 
of the Board of Scientific Counselors, National Institute of Child 
Health and Human Development, June 2, 1995, in Building 31, Room 2A52.
    This meeting will be open to the public from 9 a.m. to 12 noon on 
June 2 for the review of the Intramural Research Program and scientific 
presentations. Attendance by the public will be limited to space 
available.
    In accordance with the provisions set forth in sec. 552b(c)(6), 
Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be 
closed to the public on June 2 from 1 p.m. to adjournment for the 
review, discussion, and evaluation of individual programs and projects 
conducted by the National Institutes of Health, including consideration 
of personal qualifications and performance, the competence of 
individual investigators, and similar items, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.
    Ms. Catherine O'Connor, Senior Biomedical Research Program 
Assistant, NICHD, Building 31, Room 2A50, National Institutes of 
Health, Bethesda, Maryland, 20892-2425, Area Code 301, 496-2133, will 
provide a summary of the meeting and a roster of Blood members, and 
substantive program information upon request. Individuals who plan to 
attend the open session and need special assistance, such as sign 
language interpretation or other reasonable accommodations, should 
contact Ms. O'Connor in advance of the meeting.

    Dated: May 8, 1995.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 95-11942 Filed 5-15-95; 8:45 am]
BILLING CODE 4140-01-M
NOTE: This order is nonprecedential.



## United States Court of Appeals for the Federal Circuit 2008-1549, -1550 ORTHO-MCNEIL PHARMACEUTICAL, INC., Plaintiff-Appellant,

v. TEVA PHARMACEUTICALS INDUSTRIES, LTD., TEVA PHARMACEUTICALS USA, INC., and BARR LABORATORIES, INC., Defendants-Appellees, and KALI LABORATORIES, INC., PAR PHARMACEUTICAL COMPANIES, INC.,

and PAR PHARMACEUTICAL, INC.,

Defendants, and CARACO PHARMACEUTICAL LABORATORIES, LTD., Defendant-Appellee. Appeals from the United States District Court for the District of New Jersey in case nos. 04-CV-886 and 06-CV-3533, Judge Dennis M. Cavanaugh. ON MOTION 

### ORDER The parties jointly move for an extension of time, until February 18, 2009, for Teva Pharmaceuticals Industries, Ltd. et al. and Caraco Pharmaceutical Laboratories, Ltd. to file their briefs, and an extension of time, until March 30, 2009, for Ortho-McNeil Pharmaceutical, Inc. to file its response/reply brief. Upon consideration thereof,IT IS ORDERED THAT:

The motion is granted. FOR THE COURT 

# FEB 9 2009 /s/ Jan Horbalv Jan Horbaly Clerk Date FILED us. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

cc: Constantine L. Trela, Jr., Esq. John L. North, Esq. James F. Hurst, Esq. Arnold B. Calmann, Esq. FEB 0 9 2009

14k HORIMLI CLERK s8

2008-1549, -1550 2